PDF(Pubmed)
Abstract：
Chimeric antigen receptor (CAR) T-cell therapy has become a powerful treatment option in B-cell and plasma cell malignancies, and many patients have benefited from its use. To date, six CAR T-cell products have been approved by the FDA and EMA, and many more are being developed and investigated in clinical trials. The whole field of adoptive cell transfer has experienced an unbelievable development process, and we are now at the edge of a new era of immune therapies that will have its impact beyond hematologic malignancies. Areas of interest are, e.g., solid oncology, autoimmune diseases, infectious diseases, and others. Although much has been achieved so far, there is still a huge effort needed to overcome significant challenges and difficulties. We are witnessing a rapid expansion of knowledge, induced by new biomedical technologies and CAR designs. The era of CAR T-cell therapy has just begun, and new products will widen the therapeutic landscape in the future. This review provides a comprehensive overview of the clinical applications of CAR T-cells, focusing on the approved products and emphasizing their benefits but also indicating limitations and challenges.
摘要：
嵌合抗原受体（CAR）T细胞疗法已成为B细胞和浆细胞恶性肿瘤的有力治疗选择，许多患者受益于它的使用。迄今为止,六种CAR-T细胞产品已被FDA和EMA批准，还有更多正在临床试验中开发和研究。过继细胞转移的整个领域经历了令人难以置信的发展过程，我们现在正处于免疫疗法新时代的边缘，其影响将超越血液系统恶性肿瘤。感兴趣的领域是，例如，实体肿瘤学，自身免疫性疾病，传染病,和其他人。虽然到目前为止已经取得了很多成就，克服重大挑战和困难仍需付出巨大努力。我们目睹了知识的迅速扩张，由新的生物医学技术和CAR设计诱导。CAR-T细胞治疗的时代才刚刚开始,新产品将在未来拓宽治疗领域。本文综述了CAR-T细胞的临床应用,专注于批准的产品，强调它们的好处，但也表明局限性和挑战。
